Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Starting from the Piedmont and Aosta Valley Oncologic Network (PAVON) rare cancers database, data concerning retroperitoneal sarcoma treatment were analyzed, in order to evaluate adherence to ESMO and NCCN guidelines and the consequent impact on the quality of treatment and measurable outcomes.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.